2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3609 T-cell lymphoma arising in patients with pre-existing autoimmune disease

Omar Elghawy, MD, Steven Sher, MD, PhD2, Colin J. Thomas, MD3, Arianne Rizi4, Kimberly Carlton, RN5, Jordan S Carter, MD6, Elise A. Chong, MD7, Daniel Landsburg, MD8, Joshua D Brandstadter, MD,PhD,MSc9, Michael R Cook, MD10, Stephen J Schuster, MD11, Jakub Svoboda, MD12, Emily B. Tomasulo, DO13, Sunita Dwivedy Nasta, MD, MS14, Marco Ruella, MD15, Stefan K Barta, MD16
1 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
2 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
3 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
4 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
5 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
6 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
7 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
8 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
9 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
10 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
11 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
12 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
13 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
14 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
15 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
16 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States

Background: Autoimmune disease (AD) is a well-established lymphoma risk factor, attributed to chronic antigenic stimulation, aberrant immune activation, and immunosuppressive therapy. Existing literature on AD-associated lymphoma is overwhelmingly B-cell-focused; the clinical features and outcomes of T-cell lymphoma (TCL) in this population remain not well described. We characterized a cohort of TCL patients (pts) with pre-existing AD and evaluated whether outcomes differ by AD category.

Methods: We conducted a single-center retrospective cohort study at the University of Pennsylvania (January 2010–March 2026) of pts with pre-existing AD who developed TCL. AD was categorized by predominant immunopathogenic mechanism as either predominantly T-cell-mediated (e.g., type 1 diabetes mellitus, celiac disease, multiple sclerosis) or predominantly autoantibody/immune-complex-mediated (e.g., rheumatoid arthritis, systemic sclerosis, Sjögren's disease). Co-primary endpoints were overall survival (OS) and progression-free survival (PFS), analyzed using Kaplan–Meier methods, log-rank testing, and multivariable Cox proportional hazards models.

Results: Eighty-eight pts were identified; AD was categorized as T-cell mediated in 46 (52.3%) pts and antibody/immune-complex mediated in 42 (47.7%) pts. At TCL diagnosis, 21 (23.9%) had poorly controlled AD; 22 (25.0%) had never received immunosuppression; 26 (29.5%) had received corticosteroids alone; and 40 (45.5%) had received disease-modifying drugs. Median age at diagnosis was 65.5 years (IQR 58.2–73.6; range 21.1–90.6); 51 (58.0%) were male and 70 (79.5%) were Caucasian. Most common TCL subtypes were PTCL-NOS in 29 (33.0%), AITL/TFH in 20 (22.7%), ALK- ALCL in 17 (19.3%), and EATL in 10 (11.4%). At diagnosis, 63 (71.6%) had stage III/IV disease, 59/87 (67.8%) had B symptoms, and 15/87 (17.2%) had bulky disease (≥7.5 cm). LDH was above the upper limit of normal in 69/86 (80.2%), extranodal involvement was present in 62 (70.5%), and 53 (60.2%) had IPI 3–5. NGS was performed in 41 (46.6%) pts; among those with disease-associated variants (n=38), the most frequently altered genes were TET2 (16/38, 42%), DNMT3A (7/38, 18%), and IDH2/STAT3 (each 5/38, 13%).

Seventy-six pts received antineoplastic therapy for TCL: 52/76 (68.4%) received CHOP-like chemotherapy, 11/76 (14.5%) other chemotherapy regimens, and 13/76 (17.1%) targeted or novel therapies alone. Response to frontline therapy, evaluable in 70 pts, was CR in 31/70 (44.3%) and PR in 17/70 (24.3%), for an overall response rate of 48/70 (68.6%). Fourteen pts (15.9%) underwent autologous transplant after initial response. Median follow-up was 19.5 months (range 0.1–238.3). Median OS was 31.0 months (95% CI, 16.5–83.1), with 53 (60.2%) deaths; 24- and 60-month OS were 51.4% (40.5–62.3%) and 43.8% (32.6–55.0%). Median PFS was 8.5 months (95% CI, 6.7–13.1); 24- and 60-month PFS were 35.0% (24.6–45.4%) and 30.2% (19.8–40.5%).

On univariable analysis, stage III/IV, ECOG ≥2, extranodal involvement, and IPI 3–5 predicted inferior OS and PFS (all p≤0.036). On multivariable analysis, T-cell mediated autoimmune disease was associated with worse OS and PFS compared with antibody/immune-complex mediated disease, with an HR of 1.77 for OS (95% CI, 1.01–3.11; p=0.047) and 2.39 for PFS (95% CI, 1.38–4.13; p=0.0018). IPI remained the dominant independent predictor of both OS (adjusted HR 2.04, 95% CI 1.49–2.79, p<0.001) and PFS (adjusted HR 1.84, 95% CI 1.39–2.42, p<0.001).

Conclusions: TCL arising in pts with pre-existing AD is an aggressive disease overall, with outcomes driven primarily by standard prognostic factors such as IPI. Independent of these factors, however, pts with T-cell-mediated AD had significantly worse OS and PFS than those with antibody/immune-complex mediated AD, indicating that AD subtype carries independent prognostic weight beyond standard risk indices. Larger studies are needed to confirm these associations and disentangle the relationship between T-cell-mediated AD categories, and mechanistic studies to clarify the biological basis for the adverse impact of T-cell-mediated AD on outcomes.

Omar Elghawy, MD: No relevant conflicts of interest to declare.